Mucopolysaccharidoses (MPS) Clinical Trials

Find Mucopolysaccharidoses (MPS) Clinical Trials Near You

A Global, Open-Label, Phase I/II Trial, to Evaluate Safety, Tolerability, Pharmacodynamic and Preliminary Efficacy of JR-446 in Mucopolysaccharidosis Type IIIB (MPS IIIB)

Status: Recruiting
Location: See all (5) locations...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 1/Phase 2
SUMMARY

This is a global, open-label, Phase I/II, interventional trial in participants younger than 6 years of age with Mucopolysaccharidosis Type IIIB (MPS IIIB), designed to assess the safety and tolerability of JR-446, determine its pharmacodynamic effects, and explore its potential to demonstrate early clinical effects on disease-relevant outcomes.

Eligibility
Participation Requirements
Sex: All
Maximum Age: 5
Healthy Volunteers: f
View:

• Patients with confirmed MPS IIIB with a phenotype of MPS IIIB that is not classified as slowly progressive (i.e., not attenuated).

• A chronological age \<6 years.

• Ability to complete and achieve a Standard score ≥55, using either Bailey Scale of Infant Development-4 (BSID-4) Cognitive domain or Kaufman Assessment Battery for Children-II (KABC-II) Non-Verbal Index, whichever tool is most appropriate for the participant's chronological age.

Locations
United States
California
Children's Hospital Oakland Research Institution, Attn: 2900 Wing
RECRUITING
Oakland
Pennsylvania
UPMC Children's Hospital of Pittsburgh
NOT_YET_RECRUITING
Pittsburgh
Virginia
Lysosomal and Rare Disorders Research and Treatment Center (LDRTC)
NOT_YET_RECRUITING
Fairfax
Other Locations
Germany
University Medical Center Hamburg-Eppendorf
NOT_YET_RECRUITING
Hamburg
United Kingdom
Great Ormond Street Hospital for Children
NOT_YET_RECRUITING
London
Contact Information
Primary
JCR Pharmaceuticals Co., Ltd.
clinical_development@jp.jcrpharm.com
+81-797-32-8582
Time Frame
Start Date: 2026-09-09
Estimated Completion Date: 2028-09-30
Participants
Target number of participants: 12
Treatments
Experimental: JR-446
Arm: 1
Sponsors
Leads: JCR Pharmaceuticals Co., Ltd.
Collaborators: MEDIPAL HOLDINGS CORPORATION

This content was sourced from clinicaltrials.gov